Biocon’s subsidiary company -- Biocon Biologics India (BBIL) has received approval from board for the allotment of 88 30,456 equity shares of Rs 10 each at an issue price of Rs 254.80 per equity share (including a premium of Rs 244.80 per equity share) to Tata Capital Growth Fund II.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.